CTOs on the Move

Imago BioSciences

www.imagobio.com

 
Imago BioSciences is translating true scientific insights into transformative treatments allowing patients to live longer, disease-free lives.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Imago BioSciences raised $10M on 03/21/2019
Imago BioSciences raised $80M on 11/19/2020

Similar Companies

Kiromic

Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using our proprietary DIAMOND® artificial intelligence (AI) platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases. Kiromic is in the process of developing a multi-indication allogeneic CAR-T cell therapy that exploits the natural potency of Gamma Delta T-cells to target solid cancers. From our heritage as a cancer vaccine development company, Kiromic is focused on discovering, developing, and commercializing novel immuno-oncology applications through its robust product pipeline. Our pipeline development is leveraged through the Company`s proprietary target discovery engine called "DIAMOND," where big data science meets target identification to dramatically compress the man-years and billions of drug development dollars required to develop a live drug.

Dow Pharmaceutical Sciences

Dow Pharmaceutical Sciences is a Petaluma, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Blue Sky Biotech Inc

Blue Sky Biotech Inc is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum`s proprietary product engine, FulcrumSeek™, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.

Provident Clinical Research and Consulting

Provident Clinical Research and Consulting, Inc. is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.